Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 31 2024
0mins
Source: Benzinga
Carvana's Financial Performance: Carvana Co. shares surged 20.3% in pre-market trading after reporting third-quarter revenue of $3.66 billion and earnings of 64 cents per share, both exceeding analyst expectations.
Market Movements: Several stocks experienced significant pre-market gains, including Root, Inc. (+79.1%) and Remitly Global, Inc. (+20.7%), while others like Equillium, Inc. (-42%) and Office Properties Income Trust (-34%) saw notable declines following their quarterly results.
Analyst Views on CALC
Wall Street analysts forecast CALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CALC is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.280
Low
20.00
Averages
20.00
High
20.00
Current: 5.280
Low
20.00
Averages
20.00
High
20.00
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
